|
Volumn 11, Issue 2, 2003, Pages 123-130
|
Drug development and Alzheimer disease
|
Author keywords
[No Author keywords available]
|
Indexed keywords
2 (2 OXO 1 PYRROLIDINYL) N (5,6,7,8 TETRAHYDRO 2,3 DIMETHYLFURO[2,3 B]QUINOLIN 4 YL)ACETAMIDE;
2 [2 (1 BENZYL 4 PIPERIDINYL)ETHYL] 2,3 DIHYDRO 9 METHOXY 1H PYRROLO[3,4 B]QUINOLIN 1 ONE;
7 METHOXYTACRINE;
ABPI 124;
AMIRIDINE;
AMYLOID;
ANSECULIN;
APOLIPOPROTEIN E4;
ATORVASTATIN;
CEREBROLYSIN;
DONEPEZIL;
ESTROGEN;
FASORACETAM;
GALANTAMINE;
GANSTIGMINE;
MEMANTINE;
METHANOSULFONYL FLUORIDE;
METRIFONATE;
MONTIRELIN;
NAPROXEN;
NICERGOLINE;
NIFIRACETAM;
P 11149;
PHENSERINE;
RIVASTIGMINE;
ROFECOXIB;
TACRINE;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
ZANAPEZIL;
ZANEPEZIL;
ALZHEIMER DISEASE;
AMYLOIDOSIS;
BIOINFORMATICS;
BIOTECHNOLOGY;
BRAIN METABOLISM;
CAREGIVER;
CLINICAL TRIAL;
DEMENTIA;
DISEASE MODEL;
DRUG DEVELOPMENT;
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG MECHANISM;
DRUG RESEARCH;
DRUG SCREENING;
FINANCIAL MANAGEMENT;
GENETIC SUSCEPTIBILITY;
GENETICS;
GLUCOSE METABOLISM;
GLUCOSE UTILIZATION;
HUMAN;
KNOCKOUT GENE;
MEDICAL LITERATURE;
NOTE;
PATHOGENESIS;
PEER REVIEW;
PHARMACOGENETICS;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
|
EID: 0037371057
PISSN: 10647481
EISSN: None
Source Type: Journal
DOI: 10.1097/00019442-200303000-00003 Document Type: Note |
Times cited : (16)
|
References (8)
|